SYBX

Synlogic is no longer an operating company. Management states plainly in the 10-K that after discontinuing the Synpheny-3 Phase 3 PKU trial in February 2024 (an internal review indicated it was 'unlikely to meet its primary endpoint'), the corporate strategy is now 'pursuing strategic initiatives to enhance stockholder value, including but not limited to, a merger or the sale of the Company.' Nasdaq deemed it a 'public shell' with 'no ongoing research and development activities or active clinical trial,' and the stock was suspended and moved to OTC on January 21, 2026. The numbers confirm the shell: FY2025 revenue was $0.00 (down 100% YoY), R&D collapsed to $43K (down 99.5%), and there are no remaining revenue-generating assets. This is not a company you can value on fundamentals because there is no business left to value.

The one genuine bull point is the balance sheet relative to price. At $0.70 on 11.7M shares the equity is worth roughly $8.2M, versus $14.7M of cash and $11.9M of stockholders' equity — so the stock trades at a discount to net cash. In a clean liquidation or a favorable reverse-merger that number could imply upside. But that is a speculation on deal terms, not an investment, and the cash is bleeding: operating cash flow was -$4.36M in FY2025 and general/administrative shell-maintenance costs (legal, audit, public-company expense) continue to erode the pile while no transaction is guaranteed — 'there can be no assurance that such activities will result in any agreements or transactions.'